Repositioning Candidate Details
| Candidate ID: | R0464 |
| Source ID: | DB01247 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Isocarboxazid |
| Synonyms: | Isocarboxazid |
| Molecular Formula: | C12H13N3O2 |
| SMILES: | CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. |
| CAS Number: | 59-63-2 |
| Molecular Weight: | 231.2505 |
| DrugBank Indication: | Isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs. Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks. |
| DrugBank Pharmacology: | In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid. |
| DrugBank MoA: | Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites. |
| Targets: | Amine oxidase [flavin-containing] A inhibitor; Amine oxidase [flavin-containing] B inhibitor |
| Inclusion Criteria: | Indication associated |
